«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年05期

页码:

714-718

栏目:

论著

出版日期:

2024-10-25

文章信息/Info

Title:

Analysis of pathogenic drug resistance and inflammatory factor changes in secondary pulmonary infection in chemotherapy patients with lung cancer

作者:

邢嘉翌¹; 龚佳晟¹; 祝佳佳²; 陆 群¹

200082 上海,上海中医药大学附属上海市中西医结合医院检验科¹
200082 上海,上海中医药大学附属上海市中西医结合医院肺病科²

Author(s):

Xing Jiayi¹;  Gong Jiasheng¹;  Zhu Jiajia²;  Lu Qun¹.

¹Clinical Laboratory, ²Department of Lung disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, ChinA

关键词:

支气管肺癌;  继发肺部感染;  耐药性;  病原菌;  炎症因子

Keywords:

Bronchiogenic carcinoma;  Secondary pulmonary infection;  Drug resistance;  Pathogenic bacteria;  Inflammatory factors

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2024.05.008

摘要:

目的 分析化疗后的肺癌患者继发肺部感染病原菌耐药性及炎症因子变化。方法 选取2019年2月至2023年2月收治我院因化疗住院的肺癌患者157例为对象。院内化疗期 间继发肺部感染69例为观察组,未继发肺部感染88例为对照组。观察组呼吸道样本测试病原菌种类,分析常见病原菌药敏试验结果,病原菌耐药率。比较两组炎性因子,包括C反应蛋白(C reactive protein, CRP)、降钙素原(procalcitonin, PCT)、肿瘤坏死因子-α(tumor necrosis factor, TNF-α)以及白介素6(interleukin-6, IL-6)。结果 观察组呼吸道样本中共检出病原菌84株,包括革兰阴性菌52株(61.91%)、革兰阳性菌26株(30.95%)、真菌6株(7.14%)。革兰氏阴性菌52株中包含,铜绿假单胞菌26株、肺炎克雷伯菌15株、鲍曼不动杆菌10株,其他1株; 革兰氏阴性菌对头孢曲松、头孢吡肟以及氨苄西林有较高抗药性,对庆大霉素、左氧氟沙星和复方新诺明有一定耐药性,对亚胺培南耐药性较低。革兰阳性菌26株中包含,金黄色葡萄球菌15株、肺炎链球菌7株、溶血性葡萄球菌4株。革兰阳性菌对青霉素、红霉素、克林霉素有较高抗药性,对利奈唑胺和庆大霉素有一定抗药性,对万古霉素和左氧氟沙星耐药率低。真菌6株中包含,白色念珠菌5株、光滑念珠菌1株。真菌对氟尿嘧啶耐药率高,对氟康唑、酮康唑和两性霉素B耐药性较低。观察组CRP(24.16±5.88)mg/L、PCT(4.21±1.96)ng/ml、TNF-α(25.76±5.34)ng/L以及IL-6(36.34±2.24)ng/L高于对照组(11.97±3.55)mg/L、(1.02±0.98)ng/ml、(18.55±4.21)ng/L、(22.68±1.08)ng/L(P<0.05)。肺癌化疗患者继发肺部感染影像学影像学表现多变,可出现大片分布的磨玻璃影与局部浸润、增生改变,可累及两个肺野,影像学吸收较慢。结论 肺癌化疗继发肺部感染患者体内病原菌类型多种,其中革兰氏阴性菌最常见,病原菌对常见抗菌药的耐药性存在差异,患者体内炎症反应增多,可依据药敏结果,结合患者临床症状给予抗菌药物。

Abstract:

Objective To analyze the changes in pathogen resistance and inflammatory factors in secondary lung infections in lung cancer patients after chemotherapy. Methods A total of 157 lung cancer patients admitted to the respiratory department from February 2019 to February 2023 were hospitalized due to chemotherapy were selected as the study subjects. There were a total of 69 patients in the observation group who developed secondary pulmonary infections, and 88 patients in the control group who did not develop secondary pulmonary infections. Respiratory samples from infected patients were sent to be tested for pathogen types. Levels of C-reactive protein(CRP), procalcitonin(PCT), tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in two groups of patients were compared. Results A total of 84 strains of pathogenic bacteria were detected in respiratory samples. Gram-negative bacteria accounted for 61.91%(n=52), while gram-positive bacteria accounted for 30.95%(n=26), and fungi accounted for 7.14%(n=6). There were differences in the resistance of different pathogens to common antibiotics. The 52 strains contained Gram-negative bacteria, 26 Pseudomonas aeruginosa, 15 Klebsiella pneumoniae, 10 Acinetobacter baumannii, and 1 other strain. Gram-negative bacteria showed high resistance to ceftriaxone, cefepime, and ampicillin, certain resistance to gentamicin, levofloxacin, and co-trimoxazole, and low resistance to imipenem.The 26 gram-positive strains, included S. aureus 15 strains, Streptococcus pneumoniae 7 strains, S. haemolytica 4 strains. Gram-positive strains showed high resistance to penicillin, erythromycin, clindamycin, some resistance to linezolid and gentamicin, and low resistance to vancomycin and levofloxacin. Fungal 6 strains included, C. albicans 5 strains and C. glabrata 1 strain. Fungal strains showed high resistance to fluorouracil and low resistance to fluconazole, ketoconazole, and amphotericin B.In observation group CRP(24.16±5.88)mg/L, PCT(4.21±1.96)ng/ml, TNF-α(25.76±5.34)ng/L, IL-6(36.34±2.24)ng/L higher than control group(11.97±3.55)mg/L,(1.02±0.98)ng/ml,(18.55±4.21)ng/L,(22.68±1.08)ng/L(P<0.05). The imaging examination of secondary lung infection in lung cancer chemotherapy patients mostly showed scattered distribution sheet infiltrative changes, which could involve both lung fields, and the imaging absorption was slower. Conclusions Pathogens in the body of lung cancer patients with secondary lung infections after chemotherapy are various, with Gram negative bacteria having the highest infection rate. There are differences in resistance to common antibiotics and strong inflammatory reactions. Clinical selection of antibiotics should be based on drug sensitivity results and the actual situation of patients.

参考文献/References:

1 Cao MM, Chen WQ. Pidemiology of lung cancer in China[J]. Thorac Cancer, 2019, 10(1): 3-7.
2 Sun DQ, Li H, Cao MM, et al. Cancer burden in China: Trends, risk factors and prevention[J]. Cancer Biol Med, 2020, 17(4): 879-895.
3 王泽洲, 郑 莹. 1990年至2020年间全球及我国肺癌的发病流行趋势及防控措施[J]. 诊断学理论与实践, 2023, 22(1): 1-7.
4 中华人民共和国国家卫生健康委员会. 原发性肺癌诊疗指南(2022年版)[J]. 中国合理用药探索, 2022, 19(9): 1-28.
5 李婧涵, 齐盈颊. 肺癌发病因素、诊断方式与治疗手段的研究进展[J]. 世界最新医学信息文摘, 2019, 19(28): 123, 125.
6 梁 岚, 周向东. 抗肿瘤中成药在晚期非小细胞肺癌治疗上的应用现状[J/CD]. 中华肺部疾病杂志(电子版), 2018, 11(3): 361-363.
7 刘志奇. 100例肺癌脑转移患者放化疗临床疗效分析[J]. 实用预防医学, 2011, 18(12): 2362-2364.
8 吴克林, 吴天英, 许 海. 卡瑞利珠单抗联合化疗对老年非小细胞肺癌患者血清细胞角蛋白19片段抗原21-1、基质金属蛋白酶9表达及肿瘤生长转移的影响[J]. 实用医学杂志, 2020, 36(20): 2830-2833.
9 韩记真. 阿米娜·曲海, 阿依古丽·买买提, 等. PDCA循环护理管理对老年晚期肺癌化疗患者继发感染和自我效能感的影响[J]. 中国医药导报, 2017, 14(34): 160-166.
10 张 培, 蔺 昕, 林 康, 等. 肺癌合并肺部感染患者病原菌分布、耐药性分析及血清炎性因子检测的临床意义[J]. 现代生物医学进展, 2021, 21(9): 1682-1686.
11 李伟伟, 崔艳慧, 蔡卫梅. 肺癌患者化疗期间发生感染的相关危险因素分析[J]. 中华医院感染学杂志, 2013, 23(6): 67-69.
12 仰 杰, 颜刚林, 高建荣. 肺癌化疗住院患者院内感染危险因素及炎症因子、T淋巴细胞亚群改变研究[J]. 湖南师范大学学报(医学版), 2020, 17(4): 100-103.
13 闵金义, 吴贤伟, 向晓媛, 等. 纤维支气管镜吸痰联合肺泡灌洗治疗对肺癌术后合并肺部感染患者病情及炎症反应的改善作用[J]. 海南医学院学报, 2017, 23(5): 691-693,697.
14 Li F, Li XY, Li ZM, et al. Erratum:βKlotho is identified as a target for theranostics in non-small cell lung cancer: Erratum[J]. Theranostics, 2020, 10(12): 5528-5529.
15 柯 洋, 闫晓倩, 赵 玲, 等. 116例肺癌患者伴肺部感染痰液标本中细菌培养结果及耐药性分析[J]. 抗感染药学, 2020, 17(2): 197-199.
16 中华人民共和国卫生部.医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5): 314-320.
17 Peter G, Kari C, John C, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming(Eighth)edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51.
18 李 勇, 付 曦, 李 林, 等. 抗菌药物联合痰热清注射液治疗肺癌患者化疗后继发肺部感染的临床疗效研究[J]. 中华医院感染学杂志, 2017, 27(24): 5576-5579.
19 陈 旭, 牛 凯, 孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(3): 341-348.
20 蔡 鹏. 同步放化疗与放疗同步联合阿帕替尼治疗Ⅲ期不能手术非小细胞肺癌的临床疗效比较[J]. 实用癌症杂志, 2018, 33(3): 454-457.
21 鲍秋红, 周 华, 陈 茜, 等. 肺癌化疗合并院内肺部感染的病原菌特点及影响因素[J]. 中国肺癌杂志, 2019, 22(12): 772-778.
22 陈力津. 肺癌患者化疗后肺部感染发生情况及影响因素研究分析[J]. 中国医学创新, 2023, 20(34): 157-161.
23 Takahiro S, Shotaro O, Naoyuki I, et al. Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer[J]. Nagoya J Med Sci, 2020, 82(1): 69-77.
24 慕玉东, 王永兴, 杨瑞繁. 肺癌化疗患者院内感染病原菌分布及药敏分析[J]. 现代肿瘤医学, 2016, 24(14): 2244-2246.
25 Karanwal AB, Parikh BJ, Goswami P, et al. Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospectiveanalysis from a single center[J]. Indian J Med Paediatric Oncol, 2013, 34(2): 85.
26 王建英, 王珊珊, 朱 俊, 等. 肺癌患者化疗后肺部感染病原菌分布及耐药性分析[J]. 检验医学, 2022, 37(4): 356-359.
27 王丽萍, 孙常铭, 张 日, 等. 肺癌患者围手术期感染血清炎症因子与N末端脑钠肽前体水平变化及临床意义[J]. 中华医院感染学杂志, 2020, 30(2): 220-223.
28 姚 达, 池惠良, 万延辉, 等. 肺癌合并肺部感染患者血清炎性因子水平变化及临床意义[J]. 中华医院感染学杂志, 2019, 29(13): 1959-1962,1988.
29 Iver P, Arne W. Lung cancer: developments, concepts, and specific aspects of the new WHO classification[J]. J Cancer Res Clin Oncol, 2016, 142(5): 895-904.
30 Takaki A, Kazuki T, Gouji T, et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers[J]. Surg Oncol, 2018, 27(1): 88-94.

备注/Memo

备注/Memo:

通信作者: 陆 群, Email: luqun0718@163.com

常用功能

更新日期/Last Update: 2024-10-25